Glaucoma surgery in the blink of an eye

One of a small number of surgeons in the world who currently perform a complicated form of glaucoma surgery, Prof. Assia has developed a novel laser device that promises to revolutionize treatment of the disease. The laser, called the OTS134 for now, is expected to give most practicing eye surgeons the ability to master complex glaucoma surgery very quickly.

Glaucoma, nicknamed the silent sight thief, is the second leading cause of blindness in the West. “Glaucoma is a serious problem that starts to cause nerve damage to people without them realizing that anything is happening to their eyesight, often before it is too late, “ says Prof. Assia, who is also the director of Ophthalmology at Meir Hospital in Israel, which treats thousands of glaucoma patients each year.

The most common surgical treatment in use today perforates the wall of the eye, often resulting in collapse of the eyeball, infection, cataract formation and other complications. A more effective and elegant approach, a specialty of Prof. Assia's, involves penetration of the eye wall to a depth of only about 95 percent, leaving a razor-thin layer intact. The difference between success and failure may amount to just a few microns.

This highly-specialized non-penetrating surgery, requiring years of rigorous training and great skill, is performed by only a small number of surgeons at leading international ophthalmology centers. But a small observation led Prof. Assia to think about a method that could make the procedure accessible to eye surgeons without the long and involved training.

“Several years ago I served as a consultant for a company that produces CO2 lasers, which are used for different kinds of cosmetic and skin surgery. Because it is a relatively strong type of laser, it was not a likely candidate for use on something as delicate as the eye. However, one of the CO2 laser's unique characteristics is that it does not function when it comes in contact with liquid. It occurred to me that this would be a perfect fit for non-penetrating surgery, because the moment the CO2 laser came in contact with the intra-ocular liquid, it would automatically shut off,” he recalls.

Working in partnership with the Israeli-based company IOPtima, Prof. Assia has already carried out a series of successful human trials. A larger worldwide study will take place this year before the company launches the OTS134 — as it plans to do in the United States — by the middle of 2008.

Glaucoma affects 3 million Americans every year, with onset around the age of 40. It is a disease that is brought on by a seemingly harmless increase of pressure in the eyeball. When this pressure builds up over time, the aging body cannot seem to correct the pressure effectively. Glaucoma eventually damages the optical nerve in the eye, with extreme tunnel vision and complete blindness ensuing.

“There are drug treatments that can reduce the intra-ocular pressure, but that means life-long treatment involving two or three kinds of eye drops three times a day," says Prof. Assia. "We find that a large number of patients don’t comply with this treatment, especially because the harmful effects of not taking the medicine properly are not immediately felt.”

Although he counsels that surgical approaches to glaucoma also carry risks, the OTS134 is a promising tool for more widespread treatment with fewer complications.

Source: American Friends of Tel Aviv University

Researchers discover correlation between birth month and short-sightedness
Planning for a summer delivery for your child? You might want to choose an ophthalmologist along with an obstetrician.
A key mechanism regulating neural stem cell development is uncovered
A research team at the Institut de recherches cliniques de Montreal (IRCM), funded by the Foundation Fighting Blindness – Canada and the Canadian Institutes of Health Research (CIHR), discovered a novel mechanism that regulates how neural stem cells of the retina generate the appropriate cell type at the right time during normal development. These findings, published today in the renowned journal Neuron, could influence the development of future cell replacement therapies for genetic eye diseases that cause blindness.
To queue or not to queue?
If there's one thing that separates humankind from the animals, it's that human beings wait in lines. To make a deposit at the bank, to pay for groceries, even to vote -- we've all learned to queue, one behind the other. And we've learned, if not to like it, then at least to grin and bear it.
Climate change target may lead to 'dangerously misguided' policies
The pledge from G8 countries to cut global emissions by 50 per cent by 2050, in an effort to cut global warming to 2ºC, could lead to ‘dangerously misguided’ climate change adaptation policies, according to new research from The University of Manchester.
Medication slows progression of myopia in children
Daily treatment with a medication called pirenzepine can slow the rate of progressive myopia, or nearsightedness, in children, reports a study in the August issue of the Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus).
Smart Contact Lenses
"Smart" contact lenses that measure pressure within the eye and dispense medication accordingly could be made possible using a new material developed by biomedical engineers at UC Davis.
Analysis of quickly stopped Rx orders provides new tool for reducing medical errors
By studying medication orders that are withdrawn ("discontinued") by physicians within 45 minutes of their origination, researchers at The University of Pennsylvania School of Medicine have demonstrated a systematic and efficient method of identifying prescribing errors. The method, they say, has value to screen for medication errors and as a teaching tool for physicians and physicians-in-training. The report is published in the July/August 2008 issue of the Journal of the American Medical Informatics Association.
Glaucoma surgery studied in medicare patients, new hope for people
Ophthalmologists (Eye M.D.s) continue to develop treatments to help the more than three million Americans with glaucoma. The July issue of Ophthalmology includes a large, national study of outcomes of incisional surgeries, used to reduce pressure inside the eye, in Medicare patients. Also covered is research that may brighten the outlook for patients with end-stage glaucoma.

Glaucoma surgery in the blink of an eye

Related stories:

News discussion: